Challenges in the Metabolomics-Based Biomarker Validation Pipeline.

Area of Science:

• Biochemistry
• Clinical Chemistry
• Biomarker Discovery

Background:

• Metabolites, reflecting genome-environment interactions, are key to novel disease biomarker discovery.
• Many metabolomics-identified biomarker candidates face challenges in clinical implementation.
• Bridging the gap between research and clinical utility requires addressing translational hurdles.

Purpose of the Study:

• To summarize pre-analytical factors, analytical validation needs, and kit development challenges for metabolite biomarkers.
• To highlight strategies for efficient application of metabolite-based markers in clinical settings.
• To facilitate the translation of novel metabolite biomarkers from research to clinical practice.

Main Methods:

• Review of pre-analytical factors (sample collection, storage) and regulatory requirements for bioanalytical method validation.
• Focus on blood as the biological matrix and liquid chromatography-tandem mass spectrometry (LC-MS/MS) for biomarker validation.
• Examination of challenges in developing commercially viable metabolomics kits.

Main Results:

• Strict protocols for sample handling and validated bioanalytical methods are essential.
• LC-MS/MS on blood samples is a key platform for biomarker validation.
• Commercial kit development presents significant hurdles for widespread adoption.

Conclusions:

• Overcoming pre-analytical, analytical, and kit development challenges is vital for translating metabolite biomarkers.
• Standardized protocols and robust validation are necessary for clinical utility.
• Understanding translational challenges is crucial for advancing metabolomics in precision medicine.